<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348087</url>
  </required_header>
  <id_info>
    <org_study_id>CAFQ056B2279</org_study_id>
    <secondary_id>2011-001952-12</secondary_id>
    <nct_id>NCT01348087</nct_id>
  </id_info>
  <brief_title>Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome</brief_title>
  <official_title>An Open-label Study to Evaluate the Long-term Safety, Tolerability and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to generate long-term safety, tolerability and efficacy data for
      AFQ056 in eligible adult patients with FXS who have participated in the CAFQ056A2212
      (NCT01253629).study and patients who have participated in the previous proof-of-concept study
      CAFQ056A2204 (NCT00718341).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 148 patients were enrolled into this treatment extension trial conducted for at least 3
      years. This extension trial was terminated after the decision to terminate the AFQ056
      development program. The decision was based on the results of two randomized, double blind,
      placebo controlled phase IIb trials in adult and adolescent FXS patients (CAFQ056A2212 and
      CAFQ056B2214respectivly), both of which failed to demonstrate efficacy in the FXS population.
      As this extension trial was terminated, only the primary objective and safety are
      represented.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study treatment AFQ056 failed to demonstrate efficacy in the adult patient with Fragile X
    Syndrome in 2 other clinical studies (CAFQ056B2214 and CAFQ056A2212)
  </why_stopped>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs).</measure>
    <time_frame>Prior to first dose in extension study, Baseline (start of study treatment in extension study) to End of trial</time_frame>
    <description>Adverse events were summarized for the open-label treatment period, where the open-label treatment period is defined based on how AEs were collected and reported according to the manner in which patients entered the current study and which treatment (AFQ056 or placebo) they were receiving in the previous study. AEs which were continuing from the core study or that started after the end of core study but prior to first dose of open-label study medication in the extension study for Category 1 patients are shown under ('Prior to Ext. first dose'). AEs which started during the open-label treatment period are presented based on the last AFQ056 dose taken on or before the onset date of the AE (25 mg bid; 50 mg bid; 75 mg bid; or 100 mg bid). No efficacy data presented as study was terminated</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Fragile X Syndrome</condition>
  <arm_group>
    <arm_group_label>AFQ056 100 mg (Bid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients initiated treatment with AFQ056 at a starting dose of 25 milligram (mg) twice daily. The dose was titrated from 25mg bid to 50mg bid, 75mg bid and 100mg bid at weekly intervals. Dose adjustments (up- and down titrations) were permitted as needed to manage any tolerability issues and to ensure that patients reach their highest tolerated dose not to exceed 100mg bid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFQ056</intervention_name>
    <description>The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths, identical in appearance, will be used.</description>
    <arm_group_label>AFQ056 100 mg (Bid)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria Group 1 patients

          -  Had to have completed the CAFQ056A2212 study or another study of AFQ056 which included
             adult FXS patients within one week of enrollment into the open-label study.

          -  Females of child-bearing potential had to follow protocol requirements with respect to
             contraception.

          -  Have a caregiver or caregivers who spent, on average, at least six hours per day with
             the patient, who were willing and capable of supervising treatment, providing input
             into efficacy and safety assessments, and accompanying the patient to study visits.

        Group 2:

          -  Had to have:

          -  Completed Study CAFQ056A2204.

          -  Completed Study CAFQ056A2212 or another study of AFQ056 which included adult patients
             with FXS but enrollment into the current study was delayed for more than a week.

          -  Discontinued prematurely from Study CAFQ056A2212 or another study of AFQ056 which
             included adult patients with FXS due to intolerability of the dosage in the patient's
             assigned treatment group.

          -  Females of child-bearing potential had to follow protocol requirements with respect to
             contraception.

          -  Have a caregiver or caregivers who spent, on average, at least six hours per day with
             the patient, who were willing and capable of supervising treatment, providing input
             into efficacy and safety assessments, and accompanying the patient to study visits

        Exclusion criteria

        Any advanced, severe or unstable disease

          -  History of severe self- injurious behavior

          -  History of uncontrolled seizure disorder or resistant to therapy within the past 2
             years (Patients who are clinically stable under anti-convulsant therapy for the past 2
             years are not excluded)

          -  History of clinically significant allergies requiring hospitalization or non- inhaled
             corticosteroid therapy (asthma, anaphylaxis, etc.)

          -  Using (or used within 6 weeks before baseline) concomitant medications that are potent
             inhibitors or inducers of CYP3A4

          -  Using glutamatergic agents (riluzole, memantine, etc.) or lithium, digoxin, or
             warfarin within 6 weeks of baseline Other protocol-defined inclusion/exclusion
             criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5575</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <zip>19063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ryde</city>
        <state>New South Wales</state>
        <zip>2112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caulfield</city>
        <state>Victoria</state>
        <zip>3161</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6Y 1M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sant Cugat</city>
        <state>Catalunya</state>
        <zip>08190</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH10 5HF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <results_first_submitted>September 9, 2015</results_first_submitted>
  <results_first_submitted_qc>April 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 25, 2016</results_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fragile X Syndrome</keyword>
  <keyword>Martin-Bell Syndrome</keyword>
  <keyword>Genetic Diseases</keyword>
  <keyword>X-Linked</keyword>
  <keyword>Escalante's syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fragile X Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 28 centers in 10 countries</recruitment_details>
      <pre_assignment_details>A total of 148 patients were enrolled and treated, including 1 patient who discontinued and was later re-enrolled under a new patient number. Category 1 patients received AFQ056 in the core study and enrolled in the extension within 7 days of completing the core study; Category 2 included all other patients enrolled into the extension study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AFQ056 Total</title>
          <description>Participants from a previous AFQ056 study who entered the open-label extension study were administered AFQ056 capsules at a starting dose of 25 milligram (mg) twice daily (bid) and then titrated to 50 mg bid, 75 mg bid and 100 mg bid at weekly intervals</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AFQ056</title>
          <description>Participants from a previous AFQ056 study who entered the open-label extension study were administered AFQ056 capsules at a starting dose of 25 milligram (mg) twice daily (bid) and then titrated to 50 mg bid, 75 mg bid and 100 mg bid at weekly intervals</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs).</title>
        <description>Adverse events were summarized for the open-label treatment period, where the open-label treatment period is defined based on how AEs were collected and reported according to the manner in which patients entered the current study and which treatment (AFQ056 or placebo) they were receiving in the previous study. AEs which were continuing from the core study or that started after the end of core study but prior to first dose of open-label study medication in the extension study for Category 1 patients are shown under (‘Prior to Ext. first dose’). AEs which started during the open-label treatment period are presented based on the last AFQ056 dose taken on or before the onset date of the AE (25 mg bid; 50 mg bid; 75 mg bid; or 100 mg bid). No efficacy data presented as study was terminated</description>
        <time_frame>Prior to first dose in extension study, Baseline (start of study treatment in extension study) to End of trial</time_frame>
        <population>The analysis was performed in the safety set (SS) population, defined as participants who received at least one dose of study medication and had at least one safety assessment occurring after first dose of extension study medication. Here, 'Number of Participants Analyzed' signifies those participants who were evaluable for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Prior to Ext First Dose</title>
          </group>
          <group group_id="O2">
            <title>AFQ056 25mg Bid</title>
          </group>
          <group group_id="O3">
            <title>AFQ056 50mg Bid</title>
          </group>
          <group group_id="O4">
            <title>AFQ056 75mg Bid</title>
          </group>
          <group group_id="O5">
            <title>AFQ056 100mg Bid</title>
          </group>
          <group group_id="O6">
            <title>AFQ056 Total</title>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs).</title>
          <description>Adverse events were summarized for the open-label treatment period, where the open-label treatment period is defined based on how AEs were collected and reported according to the manner in which patients entered the current study and which treatment (AFQ056 or placebo) they were receiving in the previous study. AEs which were continuing from the core study or that started after the end of core study but prior to first dose of open-label study medication in the extension study for Category 1 patients are shown under (‘Prior to Ext. first dose’). AEs which started during the open-label treatment period are presented based on the last AFQ056 dose taken on or before the onset date of the AE (25 mg bid; 50 mg bid; 75 mg bid; or 100 mg bid). No efficacy data presented as study was terminated</description>
          <population>The analysis was performed in the safety set (SS) population, defined as participants who received at least one dose of study medication and had at least one safety assessment occurring after first dose of extension study medication. Here, 'Number of Participants Analyzed' signifies those participants who were evaluable for this outcome measure</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="141"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="112"/>
                    <measurement group_id="O6" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one severe AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious or significant AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to non serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Prior to Ext.First Dose</title>
          <description>Prior to Ext.first dose</description>
        </group>
        <group group_id="E2">
          <title>AFQ056 25 mg Bid</title>
          <description>AFQ056 25 mg bid</description>
        </group>
        <group group_id="E3">
          <title>AFQ056 50 mg Bid</title>
          <description>AFQ056 50 mg bid</description>
        </group>
        <group group_id="E4">
          <title>AFQ056 75 mg Bid</title>
          <description>AFQ056 75 mg bid</description>
        </group>
        <group group_id="E5">
          <title>AFQ056 100 mg Bid</title>
          <description>AFQ056 100 mg bid</description>
        </group>
        <group group_id="E6">
          <title>AFQ056 Total</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="88" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="117" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="135"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sponsor decided to terminate this study prematurely, as the study treatment failed to demonstrate efficacy in target population in two other clinical studies: CAFQ056B2214 (NCT01357239) and CAFQ056A2212 (NCT01253629).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

